275 related articles for article (PubMed ID: 28732067)
21. Rationale for new oral contraceptive dosing.
Williams JK
Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Adverse Drug Reaction Risk in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Chisaki Y; Aoji S; Yano Y
Biol Pharm Bull; 2017; 40(6):824-829. PubMed ID: 28566626
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1129-1144. PubMed ID: 28712325
[TBL] [Abstract][Full Text] [Related]
24. [Combined hormonal contraception in cycles artificially extended].
Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
[TBL] [Abstract][Full Text] [Related]
25. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Kaunitz AM; Archer DF; Mishell DR; Foegh M
Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
[TBL] [Abstract][Full Text] [Related]
28. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.
Stanczyk FZ; Archer DF; Bhavnani BR
Contraception; 2013 Jun; 87(6):706-27. PubMed ID: 23375353
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
30. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
31. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
[TBL] [Abstract][Full Text] [Related]
32. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
33. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
Anttila L; Kunz M; Marr J
Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study.
Stocco B; Fumagalli HF; Franceschini SA; Martinez EZ; Marzocchi-Machado CM; de Sá MFS; Toloi MRT
Medicine (Baltimore); 2015 Jan; 94(4):e385. PubMed ID: 25634167
[TBL] [Abstract][Full Text] [Related]
35. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
[TBL] [Abstract][Full Text] [Related]
36. Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium.
Franceschini SA; Vieira CS; Martins WP; França JB; Ferriani RA
Contraception; 2013 Jun; 87(6):766-72. PubMed ID: 23102798
[TBL] [Abstract][Full Text] [Related]
37. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses.
Lindberg M; Foldemo A; Josefsson A; Wiréhn AB
Eur J Contracept Reprod Health Care; 2012 Apr; 17(2):106-18. PubMed ID: 22385398
[TBL] [Abstract][Full Text] [Related]
38. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
Edelman AB; Koontz SL; Nichols MD; Jensen JT
Obstet Gynecol; 2006 Mar; 107(3):657-65. PubMed ID: 16507938
[TBL] [Abstract][Full Text] [Related]
39. A look at the long-term safety of an extended-regimen OC.
Davis MG; Reape KZ; Hait H
J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
Kroll R; Ackerman R; Feldman R; Howard B; Weiss H; Hsieh J; Ricciotti N
Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
